TABLE 2.

Mean percent change from baseline in LDL−cholesterol, HDL−cholesterol, total cholesterol and serum triglycerides at 12 months

	Group		Mean % change from baseline to 12 months (95% confidence intervals)	p-values*
		N
LDL-cholesterol	Anastrozole (PAPL)	54	−2.3 (−7.64, 3.13)	0.2859
	Anastrozole (LITTP)	94	−5.4 (−9.31, −1.54)	0.0007
	Anastrozole + risedronate (SP)	59	−2.9 (−7.20, 1.38)	0.0770
HDL-cholesterol	Anastrozole (PAPL)	54	6.9 (2.79, 10.91)	0.0016
	Anastrozole (LITTP)	95	6.8 (4.02, 9.49)	< 0.0001
	Anastrozole + risedronate (SP)	60	4.0 (0.21, 7.79)	0.1070
Total cholesterol	Anastrozole (PAPL)	54	0.8 (−3.08, 4.60)	0.8647
	Anastrozole (LITTP)	95	−2.2 (−4.96, 0.67)	0.0351
	Anastrozole + risedronate (SP)	60	−0.4 (−3.27, 2.39)	0.4840
Triglycerides	Anastrozole (PAPL)	54	−0.6 (−7.15, 5.94)	0.9881
	Anastrozole (LITTP)	95	−0.7 (−5.84, 4.50)	0.4133
	Anastrozole + risedronate (SP)	60	7.0 (−5.02, 19.09)	0.4313

^*Paired t−test comparing the means at baseline and 12 months are two−sided, 95% confidence intervals (CI). All formal tests of significance are two sided with a significance level of 5%.

Abbreviations: HDL, high−density lipoprotein; LITTP, lipid intent to treat population; LDL, low-density lipoprotein; PAPL, primary analysis population for lipids; SP, secondary population. Note: variation in sample size reflects sample analysis excluded due to major protocol deviations, sample collection and study drop out over the course of 12 months.